Fidelity Investments’s Lantern Pharma LTRN Stock Holding History

Fidelity Investments’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$685	–	5661
2026 Q1	$685	Buy	+500	New	+$1.4K	﹤0.01%	5131
2025 Q3	–	Sell	-74	Closed	-$234	–	5499
2025 Q2	$234	Buy	+74	New	+$250	﹤0.01%	5087
2024 Q3	–	Sell	-530	Closed	-$2.47K	–	5640
2024 Q2	$2.47K	Buy	+530	New	+$3.19K	﹤0.01%	4690
2021 Q3	–	Sell	-1	Closed	–	–	4748
2021 Q2	$0	Buy	+1	New	+$15	﹤0.01%	4618

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Fidelity Investments's LTRN Position: Q2 2026 in Review

Fidelity Investments sold out of Lantern Pharma (LTRN) in Q2 2026, closing a stake of 500 shares — an estimated $685 sold.

Fidelity Investments first reported a position in LTRN in Q2 2021 and held it in 4 quarters. The position peaked at $2.47K in Q2 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Fidelity Investments reported no remaining Lantern Pharma position as of Q2 2026 after selling out during the quarter.
Fidelity Investments sold 500 Lantern Pharma shares in Q2 2026, an estimated $685.
Fidelity Investments first reported a position in Lantern Pharma in Q2 2021 and held it in 4 quarters.
Fidelity Investments's Lantern Pharma position peaked at $2.47K in Q2 2024.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.